Chemomab Therapeutics Ltd. (NasdaqCM: CMMB)
Health Care · Biotechnology · IL
$1.18
+0.85% today · -65.3% 1Y
Chemomab Therapeutics Ltd. (NasdaqCM: CMMB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $8.55M and employs 12 people.
Over the last twelve months the share price has lost 65.3%, trading between 1.05 and 3.50.
Tweenvest scores Chemomab Therapeutics Ltd. across four factors: quality 35/100, value 53/100. Its strongest factor is value.
CMMB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $8.55M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.01
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- $3.50
- 52-week low
- $1.05
- Avg volume (3M)
- —
- Shares outstanding
- 7.25M
- Employees
- 12
- Next earnings
- —
About Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
- ISIN
- US16385C2035
- Founded
- 2011
- Listed since
- Feb 12, 2019
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vistagen Therapeutics, Inc.NasdaqCM: VTGN | $8.88M | $0.20 | -15.29% |
| 1nKemia IUCT Group, S.A.BME: IKM | $8.80M | €— | — |
| Nanologica AB (publ)OM: NICA | $8.66M | Skr0.26 | -5.78% |
| Brainstorm Cell Therapeutics Inc.OTCPK: BCLI | $8.60M | $0.78 | -17.94% |
| Lantern Pharma Inc.NasdaqCM: LTRN | $8.54M | $0.67 | -17.76% |
| Adaptimmune Therapeutics plcOTCPK: ADAP.Y | $8.48M | $0.03 | +6.67% |
| Eusol Biotech Co.,Ltd.UNQ: 6652 | $8.45M | NT$— | — |
| Active Biotech AB (publ)OM: ACTI | $8.34M | Skr3.14 | -10.94% |
Figures last refreshed Oct 18, 2026.